ACT001 can prevent and reverse tamoxifen resistance in human breast cancer cell lines by inhibiting NF-κB activation

Xiao Han Jin, Yong Sheng Jia, Ye Hui Shi, Qiu Ying Li, Shi Qi Bao, Wen Ping Lu, Zhongsheng Tong

Research output: Contribution to journalArticle

Abstract

Endocrine therapy is one of the main treatments for estrogen receptor–positive breast cancers. Tamoxifen is the most commonly used drug for endocrine therapy. However, primary or acquired tamoxifen resistance occurs in a large proportion of breast cancer patients, leading to therapeutic failure. We found that the combination of tamoxifen and ACT001, a nuclear factor-κB (NF-κB) signaling pathway inhibitor, effectively inhibited the proliferation of both tamoxifen-sensitive and tamoxifen-resistant cells. The tamoxifen-resistant cell line MCF7R/LCC9 showed active NF-κB signaling and high apoptosis-related gene transcription, especially for antiapoptotic genes, which could be diminished by treatment with ACT001. These results demonstrate that ACT001 can prevent and reverse tamoxifen resistance by inhibiting NF-κB activation.

Original languageEnglish (US)
Pages (from-to)1386-1397
Number of pages12
JournalJournal of cellular biochemistry
Volume120
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Tamoxifen
Chemical activation
Cells
Breast Neoplasms
Cell Line
Genes
Transcription
Therapeutics
Estrogens
Apoptosis
Drug Therapy
Pharmaceutical Preparations

Keywords

  • ACT001
  • apoptosis
  • breast neoplasms
  • endocrine therapy
  • nuclear factor-κB
  • tamoxifen resistance

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

ACT001 can prevent and reverse tamoxifen resistance in human breast cancer cell lines by inhibiting NF-κB activation. / Jin, Xiao Han; Jia, Yong Sheng; Shi, Ye Hui; Li, Qiu Ying; Bao, Shi Qi; Lu, Wen Ping; Tong, Zhongsheng.

In: Journal of cellular biochemistry, Vol. 120, No. 2, 01.02.2019, p. 1386-1397.

Research output: Contribution to journalArticle

Jin, Xiao Han ; Jia, Yong Sheng ; Shi, Ye Hui ; Li, Qiu Ying ; Bao, Shi Qi ; Lu, Wen Ping ; Tong, Zhongsheng. / ACT001 can prevent and reverse tamoxifen resistance in human breast cancer cell lines by inhibiting NF-κB activation. In: Journal of cellular biochemistry. 2019 ; Vol. 120, No. 2. pp. 1386-1397.
@article{a3c9ca78c6bf4b3db331f755a31b922a,
title = "ACT001 can prevent and reverse tamoxifen resistance in human breast cancer cell lines by inhibiting NF-κB activation",
abstract = "Endocrine therapy is one of the main treatments for estrogen receptor–positive breast cancers. Tamoxifen is the most commonly used drug for endocrine therapy. However, primary or acquired tamoxifen resistance occurs in a large proportion of breast cancer patients, leading to therapeutic failure. We found that the combination of tamoxifen and ACT001, a nuclear factor-κB (NF-κB) signaling pathway inhibitor, effectively inhibited the proliferation of both tamoxifen-sensitive and tamoxifen-resistant cells. The tamoxifen-resistant cell line MCF7R/LCC9 showed active NF-κB signaling and high apoptosis-related gene transcription, especially for antiapoptotic genes, which could be diminished by treatment with ACT001. These results demonstrate that ACT001 can prevent and reverse tamoxifen resistance by inhibiting NF-κB activation.",
keywords = "ACT001, apoptosis, breast neoplasms, endocrine therapy, nuclear factor-κB, tamoxifen resistance",
author = "Jin, {Xiao Han} and Jia, {Yong Sheng} and Shi, {Ye Hui} and Li, {Qiu Ying} and Bao, {Shi Qi} and Lu, {Wen Ping} and Zhongsheng Tong",
year = "2019",
month = "2",
day = "1",
doi = "10.1002/jcb.27146",
language = "English (US)",
volume = "120",
pages = "1386--1397",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - ACT001 can prevent and reverse tamoxifen resistance in human breast cancer cell lines by inhibiting NF-κB activation

AU - Jin, Xiao Han

AU - Jia, Yong Sheng

AU - Shi, Ye Hui

AU - Li, Qiu Ying

AU - Bao, Shi Qi

AU - Lu, Wen Ping

AU - Tong, Zhongsheng

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Endocrine therapy is one of the main treatments for estrogen receptor–positive breast cancers. Tamoxifen is the most commonly used drug for endocrine therapy. However, primary or acquired tamoxifen resistance occurs in a large proportion of breast cancer patients, leading to therapeutic failure. We found that the combination of tamoxifen and ACT001, a nuclear factor-κB (NF-κB) signaling pathway inhibitor, effectively inhibited the proliferation of both tamoxifen-sensitive and tamoxifen-resistant cells. The tamoxifen-resistant cell line MCF7R/LCC9 showed active NF-κB signaling and high apoptosis-related gene transcription, especially for antiapoptotic genes, which could be diminished by treatment with ACT001. These results demonstrate that ACT001 can prevent and reverse tamoxifen resistance by inhibiting NF-κB activation.

AB - Endocrine therapy is one of the main treatments for estrogen receptor–positive breast cancers. Tamoxifen is the most commonly used drug for endocrine therapy. However, primary or acquired tamoxifen resistance occurs in a large proportion of breast cancer patients, leading to therapeutic failure. We found that the combination of tamoxifen and ACT001, a nuclear factor-κB (NF-κB) signaling pathway inhibitor, effectively inhibited the proliferation of both tamoxifen-sensitive and tamoxifen-resistant cells. The tamoxifen-resistant cell line MCF7R/LCC9 showed active NF-κB signaling and high apoptosis-related gene transcription, especially for antiapoptotic genes, which could be diminished by treatment with ACT001. These results demonstrate that ACT001 can prevent and reverse tamoxifen resistance by inhibiting NF-κB activation.

KW - ACT001

KW - apoptosis

KW - breast neoplasms

KW - endocrine therapy

KW - nuclear factor-κB

KW - tamoxifen resistance

UR - http://www.scopus.com/inward/record.url?scp=85056750606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056750606&partnerID=8YFLogxK

U2 - 10.1002/jcb.27146

DO - 10.1002/jcb.27146

M3 - Article

VL - 120

SP - 1386

EP - 1397

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 2

ER -